Movement Alert｜Abivax S.A. Falls 5.07% in Regular Trading, Target Price Cut Weighs on Sentiment

Market Focus10-23

On October 23, Abivax S.A. fell 5.07% in Regular Trading, trading at $88.76, with turnover of $39.23 million.

The move was accompanied by a fresh analyst action: Wedbush lowered its price target on the company to $96 from $118 while maintaining a Neutral rating, pressuring near-term sentiment despite continued focus on the lead asset obefazimod.

Background details show the company previously reported H1 EPS of negative $2.43, missing the consensus estimate of negative $1.08, while sales of $2.959 million exceeded the $1.860 million estimate. Abivax S.A. has also reiterated plans to submit its first NDA by year-end for obefazimod in moderately to severely active ulcerative colitis. The latest target reduction follows an earlier September cut after the H1 release, suggesting the market is still digesting a more cautious valuation stance even as the core pipeline remains the central long-term driver.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment